

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 5, 2008

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On November 5, 2008, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its fourth fiscal quarter and fiscal year ending September 30, 2008. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (GAAP), as follows:

- **Revenues.** We present international and total company revenue growth rates at constant foreign exchange rates. We believe that presenting revenue growth rates at constant foreign exchange rates allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.
- **Operating Income.** We present BD’s operating income, both alone and as a percentage of revenues, for fiscal year 2007 after excluding the impact of the in-process research and development (“R&D”) charges relating to our acquisitions of Plasso Technology, Ltd. (“Plasso”) and TriPath Imaging, Inc. (“TriPath”). These charges affected reported operating income for the 2007 fiscal year, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of operating income are more indicative of BD’s underlying performance for the 2007 fiscal year, and allow investors to more easily compare BD’s performance for the period to other periods.
- **Effective Tax Rate.** We present BD’s effective tax rate for the 2007 fiscal year after excluding the impact of the in-process R&D charges relating to our acquisition of TriPath and Plasso. These charges, which are not considered part of ordinary operations by management and are not tax deductible, caused our effective tax rate for the 2007 fiscal year to be higher than it otherwise would have been. Management believes that this adjusted measure of our effective tax rate is more indicative of BD’s underlying results, and allows investors to more easily compare BD’s effective tax rate for the 2007 fiscal year to other periods.
- **Income from Continuing Operations.** We present BD’s income from continuing operations, both alone and as a percentage of revenues, for fiscal year 2007 after excluding the impact of the in-process R&D charges relating to our acquisition of TriPath and Plasso. These charges affected reported income from continuing operations for the 2007 fiscal year, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of income from continuing operations are more indicative of BD’s underlying performance for the 2007 fiscal year, and allow investors to more easily compare BD’s performance for the period to other periods.
- **Earnings Per Share.** We present BD’s earnings per share from continuing operations for fiscal year 2007 after excluding the impact of the in-process R&D charges relating to our acquisition of TriPath and Plasso. These charges caused reported earnings per share for the 2007 fiscal year to be lower than it otherwise would have been, although these charges are not considered by management to be part of ordinary operations. We believe that a measure of earnings per share that is adjusted for the impact of these charges is more indicative of BD’s underlying performance and allows investors to more easily compare BD’s results for the 2007 fiscal year to other periods.

BD’s management uses each of these non-GAAP measures in its own evaluation of BD’s performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD’s financial results. Management believes the non-GAAP results provide a reasonable measure of BD’s underlying performance before the effects of items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD’s results.

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

Becton, Dickinson and Company (“BD”) has elected Vincent A. Forlenza, 55, as President of BD, effective January 1, 2009, succeeding Edward J. Ludwig in that role. Mr. Ludwig will remain Chairman and Chief Executive Officer of BD. Mr. Forlenza has served as Executive Vice President since June 2006, as President— BD Biosciences from March 2003 to June 2006, and, prior thereto, as Senior Vice President— Technology, Strategy and Development.

BD has also elected David V. Elkins, 40, as Executive Vice President and Chief Financial Officer of BD, effective December 1, 2008, succeeding John R. Considine as Chief Financial Officer. Mr. Considine will remain Vice Chairman of BD. Mr. Elkins joins BD from AstraZeneca, where he has served as Vice President, Chief Financial Officer, North America and Global Marketing since April 2006, as Chief Financial Officer, UK from January 2004 to January 2006, and Senior Finance Director— Gastrointestinal and Respiratory from May 2001 to December 2003.

Mr. Elkins will receive a base salary of \$500,000, and his target annual incentive award under BD’s Performance Incentive Plan will be 70% of salary. Mr. Elkins will also receive a sign-on bonus of \$220,000, and will receive an additional \$250,000 payment in January 2010 to compensate for the forfeiture of equity awards he previously received from AstraZeneca. Mr. Elkins will also receive a sign-on award of restricted stock units valued at \$300,000, based on the closing price of the BD common stock on December 1, 2008. Mr. Elkins and BD will also enter into an agreement providing for his continued employment for a period of two years following a change of control of BD, similar to agreements with other executive officers that have been previously disclosed.

A copy of the press release issued by BD in connection with these elections is attached hereto as Exhibit 99.2.

Effective January 1, 2009, BD has elected Robert G. Oliynik as Vice President and Controller. Mr. Oliynik will serve as BD’s principal accounting officer, succeeding William A. Tozzi, who has assumed another position within BD.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit 99.1 Press release dated November 5, 2008, which is furnished pursuant to Item 2.02

Exhibit 99.2 Press release dated November 5, 2008, which is furnished pursuant to Item 5.02



ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits. — Exhibit 99.1 Press release dated November 5, 2008, which is furnished pursuant to Item 2.02.

Exhibits. — Exhibit 99.2 Press release dated November 5, 2008, which is furnished pursuant to Item 5.02.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas
Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy

Date: November 5, 2008

News Release



Contact:

Patricia A. Spinella, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

BD ANNOUNCES RESULTS FOR FOURTH FISCAL QUARTER AND FULL YEAR

Franklin Lakes, NJ (November 5, 2008) – BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues of \$1.836 billion for the fourth fiscal quarter ended September 30, 2008, representing an increase of 11 percent over the prior year period. This quarter’s growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for 5 percentage points of the increase in quarterly revenues.

For the full fiscal year ended September 30, 2008, BD reported record revenues of \$7.156 billion, representing an increase of 13 percent over the prior year, which reflects an overall estimated 6 percent favorable impact from foreign currency translation that affected all segments.

“We are pleased to report another strong year for BD, one in which we exceeded our strategic and financial goals despite a challenging business environment,” said Edward J. Ludwig, Chairman, President and Chief Executive Officer. “All segments contributed to our success and growth. Implementation of disciplined spending controls enabled us to expand our operating margins as we continued to make significant capital and R&D investments to support our innovation strategy.”

Fourth Quarter Earnings and Analysis of Full Fiscal Year 2008 and 2007 Earnings

Reported diluted earnings per share from continuing operations of \$1.13 for the fourth quarter increased by 15 percent over reported diluted earnings per share from continuing operations of 98 cents for the fourth fiscal quarter of 2007.

For the twelve-month period ending September 30, 2008, reported diluted earnings per share from continuing operations were \$4.46. The following analysis (Table 1) of diluted earnings per share from continuing operations for the twelve-month periods ended September 30, 2008 and 2007 identifies specified items that affect the comparability of results between periods. As illustrated, reported diluted earnings per share from continuing operations of \$4.46 for fiscal 2008 increased by 16 percent over diluted earnings per share from continuing operations, excluding specified items, of \$3.84 for fiscal 2007.

(Table 1)

	Twelve Months Ended September 30,		
	FY2008	FY2007	% Change
Diluted EPS from Continuing Operations:	\$ 4.46	\$ 3.36	33%
Specified Items:			
In-Process Research and Development Charge	-	0.48 ⁽¹⁾	
Diluted EPS from Continuing Operations Excluding Specified Items:	\$ 4.46	\$ 3.84	16%

(1) Represents the effect on diluted earnings per share from continuing operations of the in-process research and development (“IPR&D”) charges recorded in fiscal 2007 related to the Plasso and TriPath acquisitions.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$953 million, representing an increase of 10 percent from the prior year period. Pharmaceutical Systems and Diabetes Care products led revenue growth in the segment. For the full fiscal year ended September 30, 2008, the BD Medical segment reported 11 percent revenue growth to \$3.801 billion.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$553 million, representing an increase of 11 percent from the prior year’s quarter. Sales of safety-engineered devices, cancer diagnostics products and infectious disease testing systems contributed to revenue growth. For the full fiscal year ended September 30, 2008, the BD Diagnostics segment reported revenue growth of 13 percent to \$2.160 billion.

In the BD Biosciences segment, worldwide revenues for the quarter were \$329 million, representing an increase of 16 percent from the prior year’s quarter. Demand for clinical and research instruments and reagents were the primary growth drivers. For the full fiscal year ended September 30, 2008, the BD Biosciences segment reported 16 percent revenue growth to \$1.195 billion.

Geographic Results

Fourth quarter revenues in the U.S. were \$813 million, representing an increase of 3 percent over the prior year period. Revenues outside the U.S. were \$1.023 billion, representing an increase of 19 percent over the prior year period, with approximately 9 percentage points of the increase resulting from the favorable impact from foreign currency translation.

For the full fiscal year ended September 30, 2008, revenues in the U.S. were \$3.185 billion, representing an increase of 5 percent over the prior year period. Revenues outside of the U.S. were \$3.971 billion, representing an increase of 19 percent over the prior year period, with approximately 11 percentage points of the increase resulting from the favorable impact from foreign currency translation.

Fiscal 2009 Outlook for Full Year

The Company estimates that reported revenues for the full fiscal year 2009 will increase approximately 1 to 2 percent. This performance reflects unfavorable foreign currency translation, based on current exchange rates, of an estimated 5 to 6 percentage points. The Company expects diluted earnings per share from continuing operations for the full fiscal year 2009 to increase approximately 8 to 10 percent over reported diluted earnings per share from continuing operations of \$4.46 for the fiscal year 2008.

This earnings estimate reflects anticipated operating margin improvement, which more than offsets the unfavorable impact from foreign currency translation.

Conference Call Information

A conference call regarding BD's fourth fiscal quarter and full year results and its expectations for fiscal year 2009 will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Wednesday, November 5, 2008. The conference call will be available for replay through the close of business on November 12, 2008 on BD's website, www.bd.com/investors, or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international), access code 67742305.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2009 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current downturn in the world financial markets and major economies on our ability to access credit markets and finance our operations or the demand for our products and services; changes in interest or foreign currency exchange rates, particularly in light of increased volatility in currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation, including changes in government pricing and reimbursement policies or other cost containment reforms; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

	Three Months Ended September 30,		
	2008	2007	% Change
REVENUES	\$ 1,835,631	\$ 1,651,101	11.2
Cost of products sold	891,546	807,377	10.4
Selling and administrative	437,216	399,525	9.4
Research and development	108,606	100,430	8.1
TOTAL OPERATING COSTS AND EXPENSES	1,437,368	1,307,332	9.9
OPERATING INCOME	398,263	343,769	15.9
Interest income	6,879	9,083	(24.3)
Interest expense	(8,889)	(10,268)	(13.4)
Other expense, net	(1,734)	(4,334)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	394,519	338,250	16.6
Income tax provision	110,541	89,142	24.0
INCOME FROM CONTINUING OPERATIONS	283,978	249,108	14.0
(LOSS)/INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT)/PROVISION OF \$(1,103) AND \$1,176, RESPECTIVELY	(1,804)	10,704	NM
NET INCOME	\$ 282,174	\$ 259,812	8.6
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.16	\$ 1.02	13.7
(Loss)/Income from discontinued operations	\$ (0.01)	\$ 0.04	NM
Net income ⁽¹⁾	\$ 1.16	\$ 1.07	8.4
Diluted:			
Income from continuing operations	\$ 1.13	\$ 0.98	15.3
(Loss)/Income from discontinued operations	\$ (0.01)	\$ 0.04	NM
Net income ⁽¹⁾	\$ 1.12	\$ 1.03	8.7
AVERAGE SHARES OUTSTANDING			
Basic	243,863	243,841	
Diluted	251,197	253,009	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

	Twelve Months Ended September 30,		
	2008	2007	% Change
REVENUES	\$ 7,155,910	\$ 6,359,708	12.5
Cost of products sold	3,492,561	3,071,921	13.7
Selling and administrative	1,715,045	1,602,404	7.0
Research and development	396,238	360,050	10.1
Acquired in-process research and development	-	122,133	NM
TOTAL OPERATING COSTS AND EXPENSES	5,603,844	5,156,508	8.7
OPERATING INCOME	1,552,066	1,203,200	29.0
Interest income	39,368	46,221	(14.8)
Interest expense	(36,343)	(46,420)	(21.7)
Other (expense)/income, net	(1,484)	944	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	1,553,607	1,203,945	29.0
Income tax provision	425,689	347,778	22.4
INCOME FROM CONTINUING OPERATIONS	1,127,918	856,167	31.7
(LOSS)/INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT)/PROVISION OF \$(567) AND \$15,242, RESPECTIVELY	(922)	33,866	NM
NET INCOME	\$ 1,126,996	\$ 890,033	26.6
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 4.62	\$ 3.50	32.0
Income from discontinued operations	\$ -	\$ 0.14	NM
Net income (1)	\$ 4.61	\$ 3.63	27.0
Diluted:			
Income from continuing operations	\$ 4.46	\$ 3.36	32.7
Income from discontinued operations	\$ -	\$ 0.13	NM
Net income	\$ 4.46	\$ 3.49	27.8
AVERAGE SHARES OUTSTANDING			
Basic	244,323	244,929	
Diluted	252,681	254,810	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
(Unaudited; Amounts in thousands, except per share data)

	Twelve Months Ended September 30, 2007			
	As Reported	TriPath IPR&D (1)	Plasso IPR&D (1)	Excluding Items
Operating Income	\$ 1,203,200	\$ 114,739	\$ 7,394	1,325,333
as a % of revenues	18.9%			20.8%
Income taxes	347,778	-	-	347,778
effective tax rate	28.9%			26.2%
Income from continuing operations	856,167	114,739	7,394	978,300
as a % of revenues	13.5%			15.4%
<u>Diluted earnings per share</u>				
Income from continuing operations	\$ 3.36	\$ 0.45	\$ 0.03	\$ 3.84

(1) Represents the acquired in-process research and development charges of \$114,739 and \$7,394 related to the TriPath and Plasso acquisitions, respectively.

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

	Three Months Ended September 30,		
	2008	2007	% Change
BD MEDICAL			
United States	\$ 394,634	\$ 392,166	0.6
International	558,437	476,128	17.3
TOTAL	\$ 953,071	\$ 868,294	9.8
BD DIAGNOSTICS			
United States	\$ 281,148	\$ 272,743	3.1
International	271,918	225,206	20.7
TOTAL	\$ 553,066	\$ 497,949	11.1
BD BIOSCIENCES			
United States	\$ 136,749	\$ 125,367	9.1
International	192,745	159,491	20.9
TOTAL	\$ 329,494	\$ 284,858	15.7
TOTAL REVENUES			
United States	\$ 812,531	\$ 790,276	2.8
International	1,023,100	860,825	18.9
TOTAL	\$ 1,835,631	\$ 1,651,101	11.2

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

	Twelve Months Ended September 30,		
	2008	2007	% Change
BD MEDICAL			
United States	\$ 1,592,322	\$ 1,538,308	3.5
International	2,208,681	1,882,362	17.3
TOTAL	\$ 3,801,003	\$ 3,420,670	11.1
BD DIAGNOSTICS			
United States	\$ 1,121,843	\$ 1,054,388	6.4
International	1,037,968	850,717	22.0
TOTAL	\$ 2,159,811	\$ 1,905,105	13.4
BD BIOSCIENCES			
United States	\$ 470,641	\$ 440,309	6.9
International	724,455	593,624	22.0
TOTAL	\$ 1,195,096	\$ 1,033,933	15.6
TOTAL REVENUES			
United States	\$ 3,184,806	\$ 3,033,005	5.0
International	3,971,104	3,326,703	19.4
TOTAL	\$ 7,155,910	\$ 6,359,708	12.5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)

	United States		
	2008	2007	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 248,111	\$ 243,427	1.9
Diabetes Care	102,592	98,384	4.3
Pharmaceutical Systems	37,512	44,376	(15.5)
Ophthalmic Systems	6,419	5,979	7.4
TOTAL	\$ 394,634	\$ 392,166	0.6
BD DIAGNOSTICS			
Preanalytical Systems	\$ 145,987	\$ 138,203	5.6
Diagnostic Systems	135,161	134,540	0.5
TOTAL	\$ 281,148	\$ 272,743	3.1
BD BIOSCIENCES			
Cell Analysis (1)	\$ 98,883	\$ 85,133	16.2
Discovery Labware	37,866	40,234	(5.9)
TOTAL	\$ 136,749	\$ 125,367	9.1
TOTAL UNITED STATES	\$ 812,531	\$ 790,276	2.8

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

			International		
	2008	2007	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 261,190	\$ 233,366	11.9	4.6	7.3
Diabetes Care	95,921	82,851	15.8	6.6	9.2
Pharmaceutical Systems	188,773	149,023	26.7	14.1	12.6
Ophthalmic Systems	12,553	10,888	15.3	7.7	7.6
TOTAL	\$ 558,437	\$ 476,128	17.3	8.0	9.3
BD DIAGNOSTICS					
Preanalytical Systems	\$ 141,119	\$ 122,337	15.4	6.8	8.6
Diagnostic Systems	130,799	102,869	27.2	18.7	8.5
TOTAL	\$ 271,918	\$ 225,206	20.7	12.2	8.5
BD BIOSCIENCES					
Cell Analysis (1)	\$ 154,719	\$ 126,515	22.3	14.7	7.6
Discovery Labware	38,026	32,976	15.3	6.8	8.5
TOTAL	\$ 192,745	\$ 159,491	20.9	13.0	7.9
TOTAL INTERNATIONAL	\$ 1,023,100	\$ 860,825	18.9	10.1	8.8

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

	2008	2007	Total		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 509,301	\$ 476,793	6.8	3.3	3.5
Diabetes Care	198,513	181,235	9.5	5.4	4.1
Pharmaceutical Systems	226,285	193,399	17.0	7.3	9.7
Ophthalmic Systems	18,972	16,867	12.5	7.5	5.0
TOTAL	\$ 953,071	\$ 868,294	9.8	4.7	5.1
BD DIAGNOSTICS					
Preanalytical Systems	\$ 287,106	\$ 260,540	10.2	6.2	4.0
Diagnostic Systems	265,960	237,409	12.0	8.4	3.6
TOTAL	\$ 553,066	\$ 497,949	11.1	7.2	3.9
BD BIOSCIENCES					
Cell Analysis (1)	\$ 253,602	\$ 211,648	19.8	15.3	4.5
Discovery Labware	75,892	73,210	3.7	(0.2)	3.9
TOTAL	\$ 329,494	\$ 284,858	15.7	11.3	4.4
TOTAL REVENUES	\$ 1,835,631	\$ 1,651,101	11.2	6.6	4.6

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)

	United States		
	2008	2007	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 977,262	\$ 954,971	2.3
Diabetes Care	400,663	378,639	5.8
Pharmaceutical Systems	189,394	180,337	5.0
Ophthalmic Systems	25,003	24,361	2.6
TOTAL	\$ 1,592,322	\$ 1,538,308	3.5
BD DIAGNOSTICS			
Preanalytical Systems	\$ 574,378	\$ 541,415	6.1
Diagnostic Systems	547,465	512,973	6.7
TOTAL	\$ 1,121,843	\$ 1,054,388	6.4
BD BIOSCIENCES			
Cell Analysis (1)	\$ 324,698	\$ 290,370	11.8
Discovery Labware	145,943	149,939	(2.7)
TOTAL	\$ 470,641	\$ 440,309	6.9
TOTAL UNITED STATES	\$ 3,184,806	\$ 3,033,005	5.0

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

			International		
	2008	2007	Reported	% Change	
				FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 1,027,592	\$ 909,109	13.0	4.0	9.0
Diabetes Care	374,657	317,342	18.1	7.0	11.1
Pharmaceutical Systems	752,742	611,563	23.1	9.7	13.4
Ophthalmic Systems	53,690	44,348	21.1	10.7	10.4
TOTAL	\$ 2,208,681	\$ 1,882,362	17.3	6.5	10.8
BD DIAGNOSTICS					
Preanalytical Systems	\$ 549,150	\$ 465,276	18.0	7.3	10.7
Diagnostic Systems	488,818	385,441	26.8	16.6	10.2
TOTAL	\$ 1,037,968	\$ 850,717	22.0	11.5	10.5
BD BIOSCIENCES					
Cell Analysis (1)	\$ 575,813	\$ 465,661	23.7	13.5	10.2
Discovery Labware	148,642	127,963	16.2	5.8	10.4
TOTAL	\$ 724,455	\$ 593,624	22.0	11.8	10.2
TOTAL INTERNATIONAL	\$ 3,971,104	\$ 3,326,703	19.4	8.7	10.7

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

			Total		
	2008	2007	Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 2,004,854	\$ 1,864,080	7.6	3.1	4.5
Diabetes Care	775,320	695,981	11.4	6.3	5.1
Pharmaceutical Systems	942,136	791,900	19.0	8.6	10.4
Ophthalmic Systems	78,693	68,709	14.5	7.8	6.7
TOTAL	\$ 3,801,003	\$ 3,420,670	11.1	5.1	6.0
BD DIAGNOSTICS					
Preanalytical Systems	\$ 1,123,528	\$ 1,006,691	11.6	6.7	4.9
Diagnostic Systems	1,036,283	898,414	15.3	11.0	4.3
TOTAL	\$ 2,159,811	\$ 1,905,105	13.4	8.7	4.7
BD BIOSCIENCES					
Cell Analysis (1)	\$ 900,511	\$ 756,031	19.1	12.8	6.3
Discovery Labware	294,585	277,902	6.0	1.2	4.8
TOTAL	\$ 1,195,096	\$ 1,033,933	15.6	9.7	5.9
TOTAL REVENUES	\$ 7,155,910	\$ 6,359,708	12.5	7.0	5.5

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

News Release



Contacts:

Colleen T. White, Corporate Communications – 201-847-5369

Patricia A. Spinella, Investor Relations – 201-847-5453

BD Announces Executive Appointments of President and Chief Financial Officer

Franklin Lakes, NJ (November 5, 2008) – BD (Becton, Dickinson and Company) (NYSE:BDX) today announced the appointment of Vincent A. Forlenza as President, effective January 1, 2009, and David V. Elkins as Executive Vice President and Chief Financial Officer, effective December 1, 2008.

Mr. Forlenza will report to Edward J. Ludwig, who will remain as Chairman and Chief Executive Officer. Mr. Elkins will also report to Mr. Ludwig. John R. Considine will remain as Vice Chairman.

As President, Mr. Forlenza will oversee BD's three business segments (BD Medical, BD Diagnostics and BD Biosciences), International and the Quality function. He will continue to be a member of the Office of the CEO, along with Vice Chairman John Considine, Executive Vice Presidents Gary Cohen, John Hanson and William Kozy, and David Elkins, who will join the Office of the CEO.

"Vince has a long track record of success at BD, and he has played a critical role in developing and implementing BD's strategy and vision," said Ed Ludwig. "His new role is representative of his leadership, commitment and dedication to ensuring the ongoing and future success of the Company."

Mr. Forlenza, 55, joined BD in 1980. His BD career has spanned strategic planning, marketing, general management of several business units and executive leadership. His prior roles include service in all three business segments, including service as General Manager, Hypodermic – Europe; President, Becton Dickinson Microbiology Systems; Senior Vice President, Technology, Strategy and Development; and President, BD Biosciences. He was named Executive Vice President in 2006 and was most recently responsible for leading BD Diagnostics.

Mr. Forlenza obtained his bachelor's degree in chemical engineering from Lehigh University and his MBA from Wharton Graduate School, University of Pennsylvania. He serves as chairman of The Valley Hospital Board of Trustees and is a member of the Advisory Board for the P.C. Rossin College of Engineering and Applied Sciences at Lehigh University.

- more -

Mr. Elkins, 40, will be responsible for executive management and oversight of BD's global financial operations. He joins BD from AstraZeneca, where he has served since 2006 as Vice President, Chief Financial Officer, North America and Global Marketing, a \$13 billion business. John Considine will continue to be responsible for Integrated Supply Chain; Information Technology; Environment, Health and Safety; Project Management and Engineering Services; and Security.

"We are very pleased to welcome David as a member of our executive management team in this key role," said Ed Ludwig. "He brings to BD a wealth of deep and diverse experience in global finance and healthcare. We look forward to leveraging his insight and expertise as we continue to implement our strategy of driving revenue growth through innovation, complemented by driving operating effectiveness and productivity."

Among Mr. Elkins' prior roles during his 12-year career with AstraZeneca are service as Chief Financial Officer, U.K.; Senior Finance Director – Gastrointestinal and Respiratory; Assistant Treasurer; Senior Finance Manager – Product Strategy and Business Development; Biotechnology Finance Manager; and Regional Finance Manager – Asia.

Mr. Elkins obtained his B.S. degree in economics from the University of Delaware, his MBA from Drexel University and his M.S. degree in Organizational Dynamics from the University of Pennsylvania. He serves on the Audit Committee of the University of Delaware and the Board of the United Way of Delaware.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
